Skip to main content
رجوع
JAZZ logo

Jazz Pharmaceuticals plc

جودة البيانات: 100%
JAZZ
NASDAQ Healthcare Biotechnology
KWD 185.01
▲ KWD 2.69 (1.48%)
القيمة السوقية: 11.39B
نطاق اليوم
KWD 180.68 KWD 185.07
نطاق 52 أسبوعًا
KWD 95.49 KWD 198.00
حجم التداول
1,476,713
متوسط 50 يوم / 200 يوم
KWD 173.53 / KWD 144.04
الإغلاق السابق
KWD 182.32

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -32.0 0.3
P/B 2.6 2.9
ROE % -8.5 3.7
Net Margin % -8.4 3.8
Rev Growth 5Y % 8.4 10.0
D/E 1.3 0.2

السعر المستهدف للمحللين

Hold
KWD 207.860 +12.4%
Low: KWD 170.000 High: KWD 235.000
مكرر الربحية المستقبلي
7.6
ربحية السهم المستقبلية
KWD 23.927
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
4.4 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 31.982
KWD 30.754 – KWD 33.422
6 B 2
FY2029 KWD 30.877
KWD 29.691 – KWD 32.267
5.8 B 2
FY2028 KWD 26.639
KWD 19.612 – KWD 32.841
5.2 B 4

النقاط الرئيسية

Revenue grew 8.37% annually over 5 years — modest growth
Earnings declined -163.58% over the past year
Generating 1.30B in free cash flow
PEG of 0.18 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.49%
Capital efficient — spends only 1.38% of revenue on capex

النمو

Revenue Growth (5Y)
8.37%
Revenue (1Y)4.88%
Earnings (1Y)-163.58%
FCF Growth (3Y)10.20%

الجودة

Return on Equity
-8.47%
ROIC1.73%
Net Margin-8.35%
Op. Margin5.26%

الأمان

Debt / Equity
1.26
Current Ratio1.86
Interest Coverage1.15

التقييم

P/E Ratio
-31.98
P/B Ratio2.64
EV/EBITDA68.72
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4.88% Revenue Growth (3Y) 5.50%
Earnings Growth (1Y) -163.58% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8.37% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4.27B Net Income (TTM) -356.15M
ROE -8.47% ROA -3.05%
Gross Margin 88.21% Operating Margin 5.26%
Net Margin -8.35% Free Cash Flow (TTM) 1.30B
ROIC 1.73% FCF Growth (3Y) 10.20%
Safety
Debt / Equity 1.26 Current Ratio 1.86
Interest Coverage 1.15 Dividend Yield 0.00%
Valuation
P/E Ratio -31.98 P/B Ratio 2.64
P/S Ratio 2.67 PEG Ratio 0.18
EV/EBITDA 68.72 Dividend Yield 0.00%
Market Cap 11.39B Enterprise Value 15.42B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4.27B 4.07B 3.83B 3.66B 3.09B
Net Income -356.15M 560.12M 414.83M -224.06M -328.95M
EPS (Diluted) -5.84 8.65 6.10 -3.58 -5.51
Gross Profit 3.76B 3.62B 3.40B 3.12B 2.65B
Operating Income 224.42M 716.63M 578.58M -65.53M 170.28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 11.66B 12.01B 11.39B 10.84B 12.30B
Total Liabilities 7.34B 7.92B 7.66B 7.75B 8.33B
Shareholders' Equity 4.32B 4.09B 3.74B 3.09B 3.97B
Total Debt 5.42B 6.16B 5.79B 5.81B 6.15B
Cash & Equivalents 1.39B 2.41B 1.51B 881.48M 591.45M
Current Assets 4.17B 4.63B 3.44B 2.61B 2.61B
Current Liabilities 2.24B 1.04B 1.54B 933.19M 809.30M